Mutation screening and association study of the candidate prostate cancer susceptibility genes MSR1, PTEN, and KLF6

Prostate

Volumn 66, Issue 10, 2006, Pages 1052-1060

  Bar Shira, Anat ^a   Matarasso, Noa ^a,b   Rosner, Serena ^a   Bercovich, Dani ^a   Matzkin, Haim ^a,b   Orr Urtreger, Avi ^a,b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Germline mutation; Jews; KLF6; MSR1; Prostate cancer; PTEN

Indexed keywords

ADENINE; GUANINE;

ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CONTROLLED STUDY; GENE; GENE FREQUENCY; GENE MUTATION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC CONSERVATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN TISSUE; JEW; KLF6 GENE; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MSR1 GENE; POPULATION GENETICS; PRIORITY JOURNAL; PROSTATE CANCER; PTEN GENE;

ADULT; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; GERM-LINE MUTATION; HUMANS; ISRAEL; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MALE; MIDDLE AGED; MUTATION, MISSENSE; PEDIGREE; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PTEN PHOSPHOHYDROLASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; SCAVENGER RECEPTORS, CLASS A;

EID: 33745306631     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20425     Document Type: Article

References (36)

1. Ostrander EA, Markianos K, Stanford JL. Finding prostate cancer susceptibility genes. Annu Rev Genomics Hum Genet 2004;5:151-175.
2. Xu J, Zheng SL, Hawkins GA, Faith DA, Kelly B, Isaacs SD, Wiley KE, Chang B, Ewing CM, Bujnovszky P, Carpten JD, Bleecker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB. Linkage and association studies of prostate cancer susceptibility: Evidence for linkage at 8p22-23. Am J Hum Genet 2001;69(2): 341-350.
3. Wiklund F, Jonsson BA, Goransson I, Bergh A, Gronberg H. Linkage analysis of prostate cancer susceptibility: Confirmation of linkage at 8p22-23. Hum Genet 2003;112(4):414-418.
4. Maier C, Herkommer K, Hoegel J, Vogel W, Paiss T. A genomewide linkage analysis for prostate cancer susceptibility genes in families from Germany. Eur J Hum Genet 2005;13(3): 352-360.
5. Bova GS, Carter BS, Bussemakers MJ, Emi M, Fujiwara Y, Kyprianou N, Jacobs SC, Robinson JC, Epstein JI, Walsh PC. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 1993;53(17): 3869-3873.
6. Kagan J, Stein J, Babaian RJ, Joe YS, Pisters LL, Glassman AB, von Eschenbach AC, Troncoso P. Homozygous deletions at 8p22 and 8p21 in prostate cancer implicate these regions as the sites for candidate tumor suppressor genes. Oncogene 1995;11(10):2121-2126.
7. Xu J, Zheng SL, Komiya A, Mychaleckyj JC, Isaacs SD, Hu JJ, Sterling D, Lange EM, Hawkins GA, Turner A, Ewing CM, Faith DA, Johnson JR, Suzuki H, Bujnovszky P, Wiley KE, DeMarzo AM, Bova GS, Chang B, Hall MC, McCullough DL, Partin AW, Kassabian VS, Carpten JD, Bailey-Wilson JE, Trent JM, Ohar J, Bleecker ER, Walsh PC, Isaacs WB, Meyers DA. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 2002;32(2):321-325.
8. Miller DC, Zheng SL, Dunn RL, Sarma AV, Montie JE, Lange EM, Meyers DA, Xu J, Cooney KA. Germ-line mutations of the macrophage scavenger receptor 1 gene: Association with prostate cancer risk in African-American men. Cancer Res 2003;63(13):3486-3489.
9. Xu J, Zheng SL, Komiya A, Mychaleckyj JC, Isaacs SD, Chang B, Turner AR, Ewing CM, Wiley KE, Hawkins GA, Bleecker ER, Walsh PC, Meyers DA, Isaacs WB. Common sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Am J Hum Genet 2003;72(1):208-212.
10. Wang L, McDonnell SK, Cunningham JM, Hebbring S, Jacobsen SJ, Cerhan JR, Slager SL, Blute ML, Schaid DJ, Thibodeau SN. No association of germline alteration of MSR1 with prostate cancer risk. Nat Genet 2003;35(2):128-129.
11. Seppala EH, Ikonen T, Autio V, Rokman A, Mononen N, Matikainen MP, Tammela TL, Schleutker J. Germ-line alterations in MSR1 gene and prostate cancer risk. Clin Cancer Res 2003;9(14):5252-5256.
12. Gray IC, Phillips SM, Lee SJ, Neoptolemos JP, Weissenbach J, Spurr NK. Loss of the chromosomal region 10q23-25 in prostate cancer. Cancer Res 1995;55(21):4800-4803.
13. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, Jen J, Isaacs WB, Bova GS, Sidransky D. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 1997;57(22):4997-5000.
14. Feilotter HE, Nagai MA, Boag AH, Eng C, Mulligan LM. Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene 1998;16(13):1743- 1748.
15. Suzuki H, Freije D, Nusskern DR, Okami K, Cairns P, Sidransky D, Isaacs WB, Bova CS. Interfocal heterogeneity of PTEN/ MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 1998;58(2):204-209.
16. Marsh DJ, Dahia PL, Zheng Z, Liaw D, Parsons R, Gorlin RJ, Eng C. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet 1997;16(4):333-334.
17. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C, Parsons R. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997;16(1):64-67.
18. Cooney KA, Tsou HC, Petty EM, Miesfeldt S, Ping XL, Gruener AC, Peacocke M. Absence of PTEN germ-line mutations in men with a potential inherited predisposition to prostate cancer. Clin Cancer Res 1999;5(6):1387-1391.
19. Forrest MS, Edwards SM, Hamoudi RA, Dearnaley DP, Arden-Jones A, Dowe A, Murkin A, Kelly J, Teare MD, Easton DF, Knowles MA, Bishop DT, Eeles RA. No evidence of germline PTEN mutations in familial prostate cancer. J Med Genet 2000; 37(3):210-212.
20. Ittmann M. Allelic loss on chromosome 10 in prostate adenocarcinoma. Cancer Res 1996;56(9):2143-2147.
21. Trybus TM, Burgess AC, Wojno KJ, Glover TW, Macoska JA. Distinct areas of allelic loss on chromosomal regions 10p and 10q in human prostate cancer. Cancer Res 1996;56(10):2263-2267.
22. Narla G, Heath KE, Reeves HL, Li D, Giono LE, Kimmelman AC, Glucksman MJ, Narla J, Eng FJ, Chan AM, Ferrari AC, Martignetti JA, Friedman SL. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 2001;294(5551): 2563-2566.
23. Chen C, Hyytinen ER, Sun X, Helin HJ, Koivisto PA, Frierson HF Jr., Vessella RL, Dong JT. Deletion, mutation, and loss of expression of KLF6 in human prostate cancer. Am J Pathol 2003;162(4):1349-1354.
24. Koivisto PA, Hyytinen ER, Matikainen M, Tammela TL, Ikonen T, Schleutker J. Kruppel-like factor 6 germ-line mutations are infrequent in Finnish hereditary prostate cancer. J Urol 2004; 172(2):506-507.
25. Schleutker J, Baffoe-Bonnie AB, Gillanders E, Kainu T, Jones MP, Freas-Lutz D, Markey C, Gildea D, Riedesel E, Albertus J, Gibbs KD Jr., Matikainen M, Koivisto PA, Tammela T, Bailey-Wilson JE, Trent JM, Kallioniemi OP. Genome-wide scan for linkage in finnish hereditary prostate cancer (HPC) families identifies novel susceptibility loci at 11q14 and 3p25-26. Prostate 2003; 57(4):280-289.
26. Narla G, Difeo A, Reeves HL, Schaid DJ, Hirshfeld J, Hod E, Katz A, Isaacs WB, Hebbring S, Komiya A, McDonnell SK, Wiley KE, Jacobsen SJ, Isaacs SD, Walsh PC, Zheng SL, Chang BL, Friedrichsen DM, Stanford JL, Ostrander EA, Chinnaiyan AM, Rubin MA, Xu J, Thibodeau SN, Friedman SL, Martignetti JA. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res 2005;65(4):1213-1222.
27. Kedmi M, Beaudet AL, Orr-Urtreger A. Mice lacking neuronal nicotinic acetylcholine receptor beta4-subunit and mice lacking both alpha5- and beta4-subunits are highly resistant to nicotine-induced seizures. Physiol Genomics 2004;17(2):221-229.
28. Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004;13(Spec No. 1):R103-R121.
29. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat Genet 1998;19(4):348-355.
30. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, Khoo AS, Roy-Burman P, Greenberg NM, Van Dyke T, Cordon-Cardo C, Pandolfi PP. Pten dose dictates cancer progression in the prostate. PLoS Biol 2003;1(3):E59.
31. Ma X, Ziel-van der Made AC, Autar B, van der Korput HA, Vermeij M, van Duijn P, Cleutjens KB, de Krijger R, Krimpenfort P, Berns A, van der Kwast TH, Trapman J. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res 2005; 65(13):5730-5739.
32. Narla G, DiFeo A, Yao S, Banno A, Hod E, Reeves HL, Qiao RF, Camacho-Vanegas O, Levine A, Kirschenbaum A, Chan AM, Friedman SL, Martignetti JA. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Res 2005;65(13):5761-5768.
33. Goodman RM, Motulsky AG, editors. Genetic diseases among Ashkenazi Jews. New York: Raven Press; 1979.
34. Silverman RH. Implications for RNase L in Prostate Cancer Biology. Biochemistry 2003;42(7):1805-1812.
35. Rennert H, Zeigler-Johnson CM, Addya K, Finley MJ, Walker AH, Spangler E, Leonard DG, Wein A, Malkowicz SB, Rebbeck TR. Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men. Cancer Epidemiol Biomarkers Prev 2005;14(4):949-957.
36. Simard J, Dumont M, Labuda D, Sinnett D, Meloche C, El-Alfy M, Berger L, Lees E, Labrie F, Tavtigian SV. Prostate cancer susceptibility genes: Lessons learned and challenges posed. Endocr Relat Cancer 2003;10(2):225-259.